ABSTRACT
A 55-year-old female was admitted to Ogikubo Hospital for severe anemia and prolapse of a tumor from the anus, which had developed over 2 years. Rectal examination revealed a giant soft tumor. Endoscopic study revealed a lobulated giant tumor with a granular surface. Gastrografin-enema study showed a giant tumor, which was full of the rectum. Pathological examination showed a well differentiated carcinoma. No other prominent metastatic lesions were demonstrated. The transanal diagnostic resection of rectal cancer was performed in October 2010. This correct diagnosis showed both well differentiated adenocarcinoma and intramucosal carcinoma. We therefore recommend that a tumor of the lower rectum should undergo a diagnostic excision by means of either a local excision, ESD or TEM.
Subject(s)
Anal Canal/surgery , Rectal Neoplasms/surgery , Biopsy , Female , Humans , Magnetic Resonance Imaging , Middle Aged , Neoplasm Staging , Rectal Neoplasms/pathology , Tomography, X-Ray ComputedABSTRACT
UNLABELLED: Bevacizumab has been demonstrated to prolong survival in patients with metastatic colorectal cancer when used in combination with chemotherapy. We investigated the efficacy of chemotherapy administered in our general hospital for patients with metastatic colorectal cancer after the introduction of FOLFOX/FOLFIRI (+/-bevacizumab) therapy. SUBJECTS AND METHODS: The subjects in this study were 34 patients diagnosed with metastatic colorectal cancer, who received either FOLFIRI (+/- bevacizumab) or mFOLFOX6 (+/-bevacizumab) therapy in this hospital. The subjects were divided into a bevacizumab combination regimen group (those who received the regimen as first-line treatment), and a non-bevacizumab combination regimen group (those who did not receive the regimen as first-line treatment). Comparisons were made with regard to anticancer efficacy, progression-free survival time, and overall survival time. RESULTS: Comparison between the bevacizumab combination regimen group and the non-bevacizumab combination regimen group, revealed no significant difference due to the small number of relevant patients. However, the former showed a slight advantage over the latter in terms of anti-cancer efficacy and progression-free survival time. CONCLUSION: Bevacizumab is expected to contribute to the prolongation of survival in patients in our general hospital.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/pathology , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal, Humanized , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Bevacizumab , Camptothecin/administration & dosage , Camptothecin/analogs & derivatives , Camptothecin/therapeutic use , Colorectal Neoplasms/diagnostic imaging , Colorectal Neoplasms/immunology , Female , Fluorouracil/administration & dosage , Fluorouracil/therapeutic use , Hospitals, General , Hospitals, Public , Humans , Leucovorin/administration & dosage , Leucovorin/therapeutic use , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Organoplatinum Compounds/administration & dosage , Organoplatinum Compounds/therapeutic use , Survival Rate , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
A 62-year-old female was diagnosed with type 2 advanced gastric cancer in May 2003. Pathological examination showed a poorly differentiated carcinoma. Computed tomography (CT) revealed paraaortic lymph node metastasis, duodenal metastasis and ascites due to peritoneal dissemination. Chemotherapy with CDDP+S-1 was started and continued. After the chemotherapy, there were progressive diseases. Therefore, paclitaxel (PTX) was administered at a dose of 80 mg/m2/day for 3 weeks followed by a week rest. Clinical symptoms were relieved, and CT scan revealed metastatic lymph nodes were reduced after 4 cycles. After 13 cycles, MRI revealed a solitary brain mass was detected. She was resected for a right temporal-occipital brain metastatic tumor, and local cerebral irradiation was performed. After this operation, she was diagnosed with brain metastasis from advanced gastric cancer. The procedure was interrupted for about 6 months. After rehabilitation, PTX treatment was restarted as 14th cycle. She has survived without recurrence more than 30 cycles after the resection. A weekly administration of PTX may be a promising regimen as second-line chemotherapy for S-1 resistant recurrent gastric cancer.
Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Agents, Phytogenic/administration & dosage , Carcinoma/drug therapy , Oxonic Acid/therapeutic use , Paclitaxel/administration & dosage , Stomach Neoplasms/drug therapy , Tegafur/therapeutic use , Brain Neoplasms/secondary , Carcinoma/pathology , Drug Administration Schedule , Drug Combinations , Drug Resistance, Neoplasm , Female , Humans , Middle Aged , Stomach Neoplasms/pathologyABSTRACT
A 58-year-old female was admitted to Ogikubo Hospital for advanced hepatocellular carcinoma in April 2007. Pathological examination showed moderately differentiated hepatocellular carcinoma. Tumor marker increased the PIVKA-II level became 129 mAU/mL after the operation. FDG-PET was showed a solitary pelvic tumor sized about 2.5 cm in diameter. No other prominent metastatic lesions were demonstrated, so that a resection of intrapelvic tumor was performed in May 2008. The report which exhibited an asynchronism recurrence of peritoneal dissemination after hepatectomy is very rare. She has survived without a recurrence more than 13 months after the resection.
